ERBB2 and neoplasm: This multicentre study compares standard therapy with or without lapatinib in patients with MBC after HER2− primary tumor but with HER2+ CTCs [73] (see Table 3), with the underlying concept being that acquisition of HER2 positivity on CTCs may present patients with the alternate treatment option of anti-HER2 therapy.